Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Kala Pharmaceuticals Inc (KALA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Kala Pharmaceuticals Inc (Kala Pharmaceuticals) is a clinical stage pharmaceutical company that offers nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. The company's lead program MPP nanosuspension of an ophthalmic corticosteroid is under phase III clinical development for the treatment of post-surgical inflammation, meibomian gland disease, ocular inflammation, and dry eye disease. It also develops a small molecule receptor tyrosine kinase inhibitor (RTKi) program for the treatment of wet age-related macular degeneration (AMD). Kala Pharmaceuticals is funded by life science investors such as Lux Capital Management, Cam Capital, Longitude Capital Management, RA Capital Management, Third Rock Ventures and others. The company offers its products across the US. Kala Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.

Kala Pharmaceuticals Inc (KALA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Kala Pharma Raises USD68 Million in Series C Financing Round 11

Kala Pharma Raises USD7 Million in Venture Financing 13

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 14

Kala Pharma Raises USD 11.5 Million In Series A Financing 16

Kala Pharma Raises USD 6.2 Million In Seed Financing 18

Equity Offering 19

Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19

Kala Pharma Raises USD103.5 Million in IPO 21

Kala Pharmaceuticals Inc-Key Competitors 23

Kala Pharmaceuticals Inc-Key Employees 24

Kala Pharmaceuticals Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Aug 09, 2018: Kala Pharmaceuticals reports second quarter 2018 financial results 26

Mar 26, 2018: Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 28

Nov 07, 2017: Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update 30

Corporate Communications 32

Mar 05, 2018: Kala Pharmaceuticals Names Gregory Perry As Board Director and as Audit Committee Chair 32

Nov 13, 2017: Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer 33

Oct 02, 2017: Kala Pharmaceuticals Appoints Andrew I. Koven to Board of Directors 34

Product News 35

08/23/2018: Kala Pharmaceuticals announces FDA approval of INVELTYS for the treatment of post-operative inflammation and pain following ocular surgery 35

05/09/2018: Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch 37

01/05/2018: Kala Pharmaceuticals Announces New Drug Application For Inveltys (KPI-121 1%) Has Been Accepted For Review By The U.S. Food And Drug Administration 38

Product Approvals 39

Oct 25, 2017: Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS (KPI-121 1%) 39

Clinical Trials 40

Jul 31, 2018: Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease 40

Jun 19, 2018: Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan 41

Apr 09, 2018: Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS 43

Jan 05, 2018: Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease 44

May 01, 2017: Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery 46

Jan 06, 2017: Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Kala Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Kala Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Kala Pharma Raises USD68 Million in Series C Financing Round 11

Kala Pharma Raises USD7 Million in Venture Financing 13

Kala Pharma Raises USD 22.5 Million In Series B Venture Financing 14

Kala Pharma Raises USD 11.5 Million In Series A Financing 16

Kala Pharma Raises USD 6.2 Million In Seed Financing 18

Kala Pharma Raises USD71.2 Million in Public Offering of Shares 19

Kala Pharma Raises USD103.5 Million in IPO 21

Kala Pharmaceuticals Inc, Key Competitors 23

Kala Pharmaceuticals Inc, Key Employees 24

Kala Pharmaceuticals Inc, Other Locations 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Kala Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person